Abpro Holdings (ABPO) Operating Expenses (2022 - 2026)
Abpro Holdings' (ABPO) quarterly Operating Expenses came in at $933000.0 in Q1 2026, down 68.46% YoY from $3.0 million in Q1 2025, and down 50.82% on a QoQ basis from $1.9 million in Q4 2025.
Abpro Holdings (ABPO) Operating Expenses (2022 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 5 years of Operating Expenses data on file, last reported at $933000.0 in Q1 2026.
- Quarterly Operating Expenses fell 68.46% year-over-year to $933000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (down 36.89% YoY) and the FY2025 annual result came in at $8.5 million, down 16.35% from the prior year.
- Operating Expenses declined to $933000.0 in Q1 2026, from $1.9 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $10.6 million in Q4 2023 to a low of $315247.0 in Q3 2023.
- A 5-year average of $2.0 million and a median of $1.3 million in 2025 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses jumped 1699.87% — and 2024, when it slumped 73.85%.
- Tracing ABPO's Operating Expenses over 5 years: stood at $588645.0 in 2022, then jumped by 1699.87% to $10.6 million in 2023, then tumbled by 73.85% to $2.8 million in 2024, then slumped by 31.54% to $1.9 million in 2025, then plunged by 50.82% to $933000.0 in 2026.
- The last three Operating Expenses figures came in at $933000.0 (Q1 2026), $1.9 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 541.02 Mn |
| 10 | Abpro Holdings | 1.15 Mn | 1.15 Mn | - | 1.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 933,000.00 |
| Dec 31, 2025 | 1.90 Mn |
| Sep 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | 2.26 Mn |
| Mar 31, 2025 | 2.96 Mn |
| Dec 31, 2024 | 2.77 Mn |
| Sep 30, 2024 | 2.11 Mn |
| Jun 30, 2024 | 2.34 Mn |
| Mar 31, 2024 | 2.88 Mn |
| Dec 31, 2023 | 10.59 Mn |
| Sep 30, 2023 | 315,247.00 |
| Jun 30, 2023 | 420,341.00 |
| Mar 31, 2023 | 537,558.00 |
| Dec 31, 2022 | 588,645.00 |
| Sep 30, 2022 | 533,796.00 |
| Jun 30, 2022 | 434,432.00 |
| Mar 31, 2022 | 493,537.00 |